Uncategorized

Kala Pharmaceuticals Announces New Drug Application for INVELTYSTM (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration

by Business Wire • 2018/01/05 • 0 Comments

WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals today announced that the NDA for INVELTYS has been accepted for review by the U.S. FDA. PDFUA date is set for August 24, 2018.

Full Story →

← Everyday eye movements may be cause of glaucoma in people with normal intraocular pressure

Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease →

Post navigation